Citi has downgraded Moderna shares to sell, citing valuation concerns after a massive rally. The stock has climbed more than 600% over the past year. Analysts say the current price no longer reflects realistic growth prospects.
The downgrade marks a shift from Citi’s previous neutral stance on the biotech company. Moderna’s shares surged as investors bet on its COVID-19 vaccine and pipeline. That optimism pushed the stock well beyond what earnings can support.
Citi’s team argues that revenue and profit forecasts do not justify the hype. Even under optimistic assumptions, future cash flows fall short of the market’s expectations. The analysts see limited room for further upside.
Moderna’s vaccine has been a commercial success. But sustaining that momentum will require new products and broader approvals. Competition in the mRNA space is also increasing.
The company faces pressure to deliver on its pipeline beyond COVID-19. Investors have priced in flawless execution for flu, RSV, and cancer vaccines. Any delay or setback could trigger a sharp correction.
Citi’s call is not a comment on Moderna’s science or its vaccine’s effectiveness. It reflects a simple math problem: the stock price has outrun the fundamentals. Valuation matters even for breakthrough companies.
Some analysts remain bullish, pointing to long-term potential. But Citi’s downgrade highlights a growing divide on Wall Street. The debate now centers on how much future growth is already priced in.
For investors holding Moderna, the message is clear. Citi sees better opportunities elsewhere with less risk. The firm recommends locking in gains after the extraordinary run.
